SpectronRx
Peter Webner is a seasoned executive with extensive experience in the healthcare and medical technology sectors. Currently serving as Chief Operating Officer at SpectronRx since October 2022, Peter previously held roles at GE Healthcare as Global Executive MI Strategic Advisor and General Manager of Breast Oncology. Peter was also CEO of Zionexa, following a tenure as Chief Executive Officer at Cyclopharma US. Additional leadership positions include Senior Vice President of Business and Clinical Development at Zevacor and various roles at NCM-USA and Positron Corporation, focusing on business development and product management. Peter's education includes a certificate from Harvard Business School in Leading Product Development and degrees in Health Physics and Health Care Management from Manhattan University.
This person is not in any teams
This person is not in any offices
SpectronRx
1 followers
SpectronRx is a CDMO that is FDA and EMA inspected. We are licensed to handle multiple Therapeutic and Diagnostic isotopes pharmaceutical grade including Pb-212, Lu-177, Ac-225 and I-131 for various clinical applications. Spectron operates under a quality program that has been inspected by the FDA with approved drugs FDG, NaF and Ammonia. Spectron provides labeling and contract manufacturing services as it relates to Lu-177, Ac-225, I-131, I-124, I-111, Zr-89, Copper-64 and Fluorine-18.